FDA approves Datroway for HR-positive, HER2-negative breast cancer
The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...
precisionmedicineonline21m
AstraZeneca, Daiichi Sankyo Begin Phase III Trial of Datroway in High-Risk Early-Stage NSCLC
The firms will evaluate two adjuvant treatment options, Datroway with rilvegostomig or rilvegostomig monotherapy, against standard-of-care treatment.
Medscape21m
Three Cancer Medicines Green-Lighted in Europe
The European Medicines Agency has recommended three new medicines to treat breast and cervical cancer and ...
FiercePharma13d
Datroway, 2nd ADC from AstraZeneca-Daiichi collab, wins first FDA nod in breast cancer
Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the ...
ジャパンタイムズ5h
AstraZeneca and Daiichi’s breast cancer drug gets EU backing
The green light from the European Medicines Agency is the first backing in the EU for the medicine, following its approval in ...
BioPharma Dive10d
AstraZeneca, Daiichi’s Enhertu successor gets first FDA OK in breast cancer
The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...
Hosted on MSN10d
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer
AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), ...
WebMD9d
FDA Approves New Treatment for Advanced Breast Cancer
The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the ...
DATROWAY® Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
DATROWAY Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer ...
Healio10d
FDA approves Datroway for advanced breast cancer
The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.The indication ...
Business Wire9h
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer
Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...
Yahoo Finance13d
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
WILMINGTON, Del., January 17, 2025--(BUSINESS WIRE)--DATROWAY ® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone ...